<li>acebutolol<p>valsartan and acebutolol both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>acebutolol, valsartan. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of fetal compromise if given during pregnancy.</p></li><li>aceclofenac<p>valsartan and aceclofenac both increase  serum potassium. Use Caution/Monitor.</p></li><li>acemetacin<p>valsartan and acemetacin both increase  serum potassium. Use Caution/Monitor.</p></li><li>albiglutide<p>valsartan increases effects of albiglutide by Other (see comment). Use Caution/Monitor. 
Comment: Angiotensin II receptor antagonists may enhance hypoglycemic effects of antidiabetic agents by improving insulin sensitivity. Monitor patients for changes in glycemic control.</p></li><li>aldesleukin<p>aldesleukin increases effects of valsartan by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension.</p></li><li>amifostine<p>amifostine increases effects of valsartan by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension.</p></li><li>amiloride<p>valsartan and amiloride both increase  serum potassium. Modify Therapy/Monitor Closely.</p></li><li>amphetamine<p>amphetamine decreases effects of valsartan by pharmacodynamic antagonism. Use Caution/Monitor.</p></li><li>aspirin<p>valsartan and aspirin both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>aspirin decreases effects of valsartan by pharmacodynamic antagonism. Modify Therapy/Monitor Closely.  NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.<span><br><br></span>valsartan, aspirin.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>aspirin rectal<p>valsartan and aspirin rectal both increase  serum potassium. Use Caution/Monitor.</p></li><li>aspirin/citric acid/sodium bicarbonate<p>aspirin/citric acid/sodium bicarbonate decreases effects of valsartan by pharmacodynamic antagonism. Modify Therapy/Monitor Closely.  NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.<span><br><br></span>valsartan and aspirin/citric acid/sodium bicarbonate both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>valsartan, aspirin/citric acid/sodium bicarbonate.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>atenolol<p>valsartan and atenolol both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>atenolol, valsartan. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of fetal compromise if given during pregnancy.</p></li><li>atorvastatin<p>atorvastatin will increase the level or effect of valsartan by  Other (see comment). Use Caution/Monitor. The results from an in vitro study with human liver tissue indicate that valsartan is a substrate of the hepatic uptake transporter OATP1B1; coadministration with OATP1B1 inhibitors may increase valsartan systemic exposure<span><br><br></span>valsartan increases toxicity of atorvastatin by Other (see comment). Use Caution/Monitor. 
Comment: OATP1B1 inhibitors may increase risk of myopathy.</p></li><li>avanafil<p>avanafil increases effects of valsartan by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension.</p></li><li>bambuterol<p>valsartan increases and bambuterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>bendroflumethiazide<p>valsartan increases and bendroflumethiazide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>betaxolol<p>valsartan and betaxolol both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>betaxolol, valsartan. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of fetal compromise if given during pregnancy.</p></li><li>bisoprolol<p>valsartan and bisoprolol both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>bisoprolol, valsartan. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of fetal compromise if given during pregnancy.</p></li><li>brimonidine<p>brimonidine increases effects of valsartan by pharmacodynamic synergism. Use Caution/Monitor.</p></li><li>bumetanide<p>valsartan increases and bumetanide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>canagliflozin<p>valsartan and canagliflozin both increase  serum potassium. Use Caution/Monitor.</p></li><li>candesartan<p>candesartan and valsartan both increase  serum potassium. Use Caution/Monitor.</p></li><li>carbamazepine<p>carbamazepine will increase the level or effect of valsartan by  Other (see comment). Use Caution/Monitor. The results from an in vitro study with human liver tissue indicate that valsartan is a substrate of the hepatic uptake transporter OATP1B1; coadministration with OATP1B1 inhibitors may increase valsartan systemic exposure</p></li><li>carbenoxolone<p>valsartan increases and carbenoxolone decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>carvedilol<p>valsartan and carvedilol both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>carvedilol, valsartan. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of fetal compromise if given during pregnancy.</p></li><li>caspofungin<p>caspofungin will increase the level or effect of valsartan by  Other (see comment). Use Caution/Monitor. The results from an in vitro study with human liver tissue indicate that valsartan is a substrate of the hepatic uptake transporter OATP1B1; coadministration with OATP1B1 inhibitors may increase valsartan systemic exposure</p></li><li>celecoxib<p>valsartan and celecoxib both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>celecoxib decreases effects of valsartan by pharmacodynamic antagonism. Modify Therapy/Monitor Closely.  NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.<span><br><br></span>valsartan, celecoxib.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>celiprolol<p>valsartan and celiprolol both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>celiprolol, valsartan. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of fetal compromise if given during pregnancy.</p></li><li>chlorothiazide<p>valsartan increases and chlorothiazide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>chlorthalidone<p>valsartan increases and chlorthalidone decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>choline magnesium trisalicylate<p>valsartan and choline magnesium trisalicylate both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>choline magnesium trisalicylate decreases effects of valsartan by pharmacodynamic antagonism. Modify Therapy/Monitor Closely.  NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.<span><br><br></span>valsartan, choline magnesium trisalicylate.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>clarithromycin<p>clarithromycin will increase the level or effect of valsartan by  Other (see comment). Use Caution/Monitor. The results from an in vitro study with human liver tissue indicate that valsartan is a substrate of the hepatic uptake transporter OATP1B1; coadministration with OATP1B1 inhibitors may increase valsartan systemic exposure</p></li><li>cyclopenthiazide<p>valsartan increases and cyclopenthiazide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>cyclosporine<p>cyclosporine will increase the level or effect of valsartan by  Other (see comment). Use Caution/Monitor. The results from an in vitro study with human liver tissue indicate that valsartan is a substrate of the hepatic uptake transporter OATP1B1; coadministration with OATP1B1 inhibitors may increase valsartan systemic exposure</p></li><li>daclatasvir<p>daclatasvir will increase the level or effect of valsartan by  Other (see comment). Use Caution/Monitor. Daclatasvir inhibits OATP1B1, OATP1B3, and BCRP. Caution if coadministered with drugs that are substrates of these transporters.</p></li><li>dalteparin<p>dalteparin increases toxicity of valsartan by Other (see comment). Use Caution/Monitor. 
Comment: Low molecular weight heparins may suppress adrenal aldosterone secretion, which can potentially cause hyperkalemia.</p></li><li>diclofenac<p>valsartan and diclofenac both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>diclofenac decreases effects of valsartan by pharmacodynamic antagonism. Modify Therapy/Monitor Closely.  NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.<span><br><br></span>valsartan, diclofenac.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>diflunisal<p>valsartan and diflunisal both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>diflunisal decreases effects of valsartan by pharmacodynamic antagonism. Modify Therapy/Monitor Closely.  NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.<span><br><br></span>valsartan, diflunisal.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>digoxin<p>digoxin will increase the level or effect of valsartan by  Other (see comment). Use Caution/Monitor. The results from an in vitro study with human liver tissue indicate that valsartan is a substrate of the hepatic uptake transporter OATP1B1; coadministration with OATP1B1 inhibitors may increase valsartan systemic exposure<span><br><br></span>valsartan will increase the level or effect of digoxin by  decreasing renal clearance. Use Caution/Monitor. Monitor digoxin levels closely when coadministered with drugs that may decrease glomerular filtration or tubular secretion.</p></li><li>dobutamine<p>valsartan increases and dobutamine decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>dopexamine<p>valsartan increases and dopexamine decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>drospirenone<p>valsartan and drospirenone both increase  serum potassium. Modify Therapy/Monitor Closely.</p></li><li>eltrombopag<p>eltrombopag will decrease the level or effect of valsartan by  Other (see comment). Use Caution/Monitor. The results from an in vitro study with human liver tissue indicate that valsartan is a substrate of the hepatic uptake transporter OATP1B1; coadministration with OATP1B1 inhibitors may increase valsartan systemic exposure</p></li><li>enoxaparin<p>enoxaparin increases toxicity of valsartan by Other (see comment). Use Caution/Monitor. 
Comment: Low molecular weight heparins may suppress adrenal aldosterone secretion, which can potentially cause hyperkalemia.</p></li><li>ephedrine (pulmonary)<p>valsartan increases and ephedrine (pulmonary) decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.  .</p></li><li>eplerenone<p>valsartan, eplerenone. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of hyperkalemia.</p></li><li>eprosartan<p>eprosartan and valsartan both increase  serum potassium. Use Caution/Monitor.</p></li><li>erythromycin base<p>erythromycin base will increase the level or effect of valsartan by  Other (see comment). Use Caution/Monitor. The results from an in vitro study with human liver tissue indicate that valsartan is a substrate of the hepatic uptake transporter OATP1B1; coadministration with OATP1B1 inhibitors may increase valsartan systemic exposure</p></li><li>erythromycin ethylsuccinate<p>erythromycin ethylsuccinate will increase the level or effect of valsartan by  Other (see comment). Use Caution/Monitor. The results from an in vitro study with human liver tissue indicate that valsartan is a substrate of the hepatic uptake transporter OATP1B1; coadministration with OATP1B1 inhibitors may increase valsartan systemic exposure</p></li><li>erythromycin lactobionate<p>erythromycin lactobionate will increase the level or effect of valsartan by  Other (see comment). Use Caution/Monitor. The results from an in vitro study with human liver tissue indicate that valsartan is a substrate of the hepatic uptake transporter OATP1B1; coadministration with OATP1B1 inhibitors may increase valsartan systemic exposure</p></li><li>erythromycin stearate<p>erythromycin stearate will increase the level or effect of valsartan by  Other (see comment). Use Caution/Monitor. The results from an in vitro study with human liver tissue indicate that valsartan is a substrate of the hepatic uptake transporter OATP1B1; coadministration with OATP1B1 inhibitors may increase valsartan systemic exposure</p></li><li>esmolol<p>valsartan and esmolol both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>esmolol, valsartan. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of fetal compromise if given during pregnancy.</p></li><li>ethacrynic acid<p>valsartan increases and ethacrynic acid decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>etodolac<p>valsartan and etodolac both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>etodolac decreases effects of valsartan by pharmacodynamic antagonism. Modify Therapy/Monitor Closely.  NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.<span><br><br></span>valsartan, etodolac.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>etoricoxib<p>valsartan and etoricoxib both increase  serum potassium. Use Caution/Monitor.</p></li><li>exenatide injectable solution<p>valsartan increases effects of exenatide injectable solution by Other (see comment). Use Caution/Monitor. 
Comment: Angiotensin II receptor antagonists may enhance hypoglycemic effects of antidiabetic agents by improving insulin sensitivity. Monitor patients for changes in glycemic control.</p></li><li>exenatide injectable suspension<p>valsartan increases effects of exenatide injectable suspension by Other (see comment). Use Caution/Monitor. 
Comment: Angiotensin II receptor antagonists may enhance hypoglycemic effects of antidiabetic agents by improving insulin sensitivity. Monitor patients for changes in glycemic control.</p></li><li>fenbufen<p>valsartan and fenbufen both increase  serum potassium. Use Caution/Monitor.</p></li><li>fenoprofen<p>valsartan and fenoprofen both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>fenoprofen decreases effects of valsartan by pharmacodynamic antagonism. Modify Therapy/Monitor Closely.  NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.<span><br><br></span>valsartan, fenoprofen.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>flurbiprofen<p>valsartan and flurbiprofen both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>flurbiprofen decreases effects of valsartan by pharmacodynamic antagonism. Modify Therapy/Monitor Closely.  NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.<span><br><br></span>valsartan, flurbiprofen.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>fluvastatin<p>valsartan increases toxicity of fluvastatin by Other (see comment). Use Caution/Monitor. 
Comment: OATP1B1 inhibitors may increase risk of myopathy.</p></li><li>furosemide<p>valsartan increases and furosemide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>gemfibrozil<p>gemfibrozil will increase the level or effect of valsartan by  Other (see comment). Use Caution/Monitor. The results from an in vitro study with human liver tissue indicate that valsartan is a substrate of the hepatic uptake transporter OATP1B1; coadministration with OATP1B1 inhibitors may increase valsartan systemic exposure</p></li><li>gentamicin<p>valsartan increases and gentamicin decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>glyburide<p>glyburide will increase the level or effect of valsartan by  Other (see comment). Use Caution/Monitor. The results from an in vitro study with human liver tissue indicate that valsartan is a substrate of the hepatic uptake transporter OATP1B1; coadministration with OATP1B1 inhibitors may increase valsartan systemic exposure</p></li><li>heparin<p>heparin increases toxicity of valsartan by Other (see comment). Use Caution/Monitor. 
Comment: Low molecular weight heparins may suppress adrenal aldosterone secretion, which can potentially cause hyperkalemia.</p></li><li>hydrochlorothiazide<p>valsartan increases and hydrochlorothiazide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>ibuprofen<p>valsartan and ibuprofen both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>ibuprofen decreases effects of valsartan by pharmacodynamic antagonism. Modify Therapy/Monitor Closely.  NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.<span><br><br></span>valsartan, ibuprofen.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>indapamide<p>valsartan increases and indapamide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>indinavir<p>indinavir will increase the level or effect of valsartan by  Other (see comment). Use Caution/Monitor. The results from an in vitro study with human liver tissue indicate that valsartan is a substrate of the hepatic uptake transporter OATP1B1; coadministration with OATP1B1 inhibitors may increase valsartan systemic exposure</p></li><li>indomethacin<p>valsartan and indomethacin both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>indomethacin decreases effects of valsartan by pharmacodynamic antagonism. Modify Therapy/Monitor Closely.  NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.<span><br><br></span>valsartan, indomethacin.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>insulin degludec<p>valsartan, insulin degludec.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Both drugs decrease blood glucose.</p></li><li>insulin degludec/insulin aspart<p>valsartan, insulin degludec/insulin aspart.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Both drugs decrease blood glucose.</p></li><li>insulin inhaled<p>valsartan, insulin inhaled.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Both drugs decrease blood glucose.</p></li><li>irbesartan<p>irbesartan and valsartan both increase  serum potassium. Use Caution/Monitor.</p></li><li>ketoconazole<p>ketoconazole will increase the level or effect of valsartan by  Other (see comment). Use Caution/Monitor. The results from an in vitro study with human liver tissue indicate that valsartan is a substrate of the hepatic uptake transporter OATP1B1; coadministration with OATP1B1 inhibitors may increase valsartan systemic exposure</p></li><li>ketoprofen<p>valsartan and ketoprofen both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>ketoprofen decreases effects of valsartan by pharmacodynamic antagonism. Modify Therapy/Monitor Closely.  NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.<span><br><br></span>valsartan, ketoprofen.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>ketorolac<p>valsartan and ketorolac both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>ketorolac decreases effects of valsartan by pharmacodynamic antagonism. Modify Therapy/Monitor Closely.  NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.<span><br><br></span>valsartan, ketorolac.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>ketorolac intranasal<p>valsartan and ketorolac intranasal both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>ketorolac intranasal decreases effects of valsartan by pharmacodynamic antagonism. Modify Therapy/Monitor Closely.  NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.<span><br><br></span>valsartan, ketorolac intranasal.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>labetalol<p>valsartan and labetalol both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>labetalol, valsartan. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of fetal compromise if given during pregnancy.</p></li><li>levodopa<p>levodopa increases effects of valsartan by pharmacodynamic synergism. Use Caution/Monitor. Consider decreasing dosage of antihypertensive agent.</p></li><li>liraglutide<p>valsartan increases effects of liraglutide by Other (see comment). Use Caution/Monitor. 
Comment: Angiotensin II receptor antagonists may enhance hypoglycemic effects of antidiabetic agents by improving insulin sensitivity. Monitor patients for changes in glycemic control.</p></li><li>lornoxicam<p>valsartan and lornoxicam both increase  serum potassium. Use Caution/Monitor.</p></li><li>losartan<p>losartan and valsartan both increase  serum potassium. Use Caution/Monitor.</p></li><li>lovastatin<p>lovastatin will increase the level or effect of valsartan by  Other (see comment). Use Caution/Monitor. The results from an in vitro study with human liver tissue indicate that valsartan is a substrate of the hepatic uptake transporter OATP1B1; coadministration with OATP1B1 inhibitors may increase valsartan systemic exposure</p></li><li>lurasidone<p>lurasidone increases effects of valsartan by Other (see comment). Use Caution/Monitor. 
Comment: Potential  for increased risk of hypotension with concurrent use. Monitor blood pressure and adjust  dose of  antihypertensive agent as needed.</p></li><li>maitake<p>maitake increases effects of valsartan by pharmacodynamic synergism. Use Caution/Monitor.</p></li><li>maraviroc<p>maraviroc, valsartan.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of orthostatic hypotension.</p></li><li>meclofenamate<p>meclofenamate decreases effects of valsartan by pharmacodynamic antagonism. Modify Therapy/Monitor Closely.  NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.<span><br><br></span>valsartan and meclofenamate both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>valsartan, meclofenamate.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>mefenamic acid<p>valsartan and mefenamic acid both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>mefenamic acid decreases effects of valsartan by pharmacodynamic antagonism. Modify Therapy/Monitor Closely.  NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.<span><br><br></span>valsartan, mefenamic acid.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>meloxicam<p>valsartan and meloxicam both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>meloxicam decreases effects of valsartan by pharmacodynamic antagonism. Modify Therapy/Monitor Closely.  NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.<span><br><br></span>valsartan, meloxicam.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>methyclothiazide<p>valsartan increases and methyclothiazide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.  .</p></li><li>metolazone<p>valsartan increases and metolazone decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>metoprolol<p>valsartan and metoprolol both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>metoprolol, valsartan. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of fetal compromise if given during pregnancy.</p></li><li>metyrapone<p>metyrapone will increase the level or effect of valsartan by  Other (see comment). Use Caution/Monitor. The results from an in vitro study with human liver tissue indicate that valsartan is a substrate of the hepatic uptake transporter OATP1B1; coadministration with OATP1B1 inhibitors may increase valsartan systemic exposure</p></li><li>mifepristone<p>mifepristone will increase the level or effect of valsartan by  Other (see comment). Use Caution/Monitor. The results from an in vitro study with human liver tissue indicate that valsartan is a substrate of the hepatic uptake transporter OATP1B1; coadministration with OATP1B1 inhibitors may increase valsartan systemic exposure</p></li><li>nabumetone<p>valsartan and nabumetone both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>nabumetone decreases effects of valsartan by pharmacodynamic antagonism. Modify Therapy/Monitor Closely.  NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.<span><br><br></span>valsartan, nabumetone.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>nadolol<p>valsartan and nadolol both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>nadolol, valsartan. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of fetal compromise if given during pregnancy.</p></li><li>naproxen<p>valsartan and naproxen both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>naproxen decreases effects of valsartan by pharmacodynamic antagonism. Modify Therapy/Monitor Closely.  NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.<span><br><br></span>valsartan, naproxen.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>nebivolol<p>valsartan and nebivolol both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>nebivolol, valsartan. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of fetal compromise if given during pregnancy.</p></li><li>nelfinavir<p>nelfinavir will increase the level or effect of valsartan by  Other (see comment). Use Caution/Monitor. The results from an in vitro study with human liver tissue indicate that valsartan is a substrate of the hepatic uptake transporter OATP1B1; coadministration with OATP1B1 inhibitors may increase valsartan systemic exposure</p></li><li>nitroglycerin rectal<p>nitroglycerin rectal, valsartan.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Observe for possible additive hypotensive effects during concomitant use. .</p></li><li>olmesartan<p>olmesartan and valsartan both increase  serum potassium. Use Caution/Monitor.</p></li><li>ombitasvir/paritaprevir/ritonavir<p>ombitasvir/paritaprevir/ritonavir will increase the level or effect of valsartan by  Other (see comment). Use Caution/Monitor. Paritaprevir inhibits OATP1B1, OATP1B3, and BCRP. Ritonavir inhibits BCRP. Caution if coadministered with drugs that are substrates of these transporters.</p></li><li>ombitasvir/paritaprevir/ritonavir &amp; dasabuvir<p>ombitasvir/paritaprevir/ritonavir &amp; dasabuvir will increase the level or effect of valsartan by  Other (see comment). Use Caution/Monitor. May inhibit organic anion transporter polypeptides; decrease dose of angiotensin receptor  blockers and monitor patients for signs and symptoms of hypotension and/or worsening renal function; if such events occur, consider further dose reduction of angiotensin receptor blocker or switching to alternative to angiotensin receptor blocker </p></li><li>oxaprozin<p>valsartan and oxaprozin both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>oxaprozin decreases effects of valsartan by pharmacodynamic antagonism. Modify Therapy/Monitor Closely.  NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.<span><br><br></span>valsartan, oxaprozin.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>paclitaxel<p>paclitaxel will increase the level or effect of valsartan by  Other (see comment). Use Caution/Monitor. The results from an in vitro study with human liver tissue indicate that valsartan is a substrate of the hepatic uptake transporter OATP1B1; coadministration with OATP1B1 inhibitors may increase valsartan systemic exposure</p></li><li>paclitaxel protein bound<p>paclitaxel protein bound will increase the level or effect of valsartan by  Other (see comment). Use Caution/Monitor. The results from an in vitro study with human liver tissue indicate that valsartan is a substrate of the hepatic uptake transporter OATP1B1; coadministration with OATP1B1 inhibitors may increase valsartan systemic exposure</p></li><li>parecoxib<p>valsartan and parecoxib both increase  serum potassium. Use Caution/Monitor.</p></li><li>pazopanib<p>pazopanib will increase the level or effect of valsartan by  Other (see comment). Use Caution/Monitor. The results from an in vitro study with human liver tissue indicate that valsartan is a substrate of the hepatic uptake transporter OATP1B1; coadministration with OATP1B1 inhibitors may increase valsartan systemic exposure</p></li><li>penbutolol<p>valsartan and penbutolol both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>penbutolol, valsartan. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of fetal compromise if given during pregnancy.</p></li><li>pindolol<p>valsartan and pindolol both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>pindolol, valsartan. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of fetal compromise if given during pregnancy.</p></li><li>pioglitazone<p>pioglitazone will increase the level or effect of valsartan by  Other (see comment). Use Caution/Monitor. The results from an in vitro study with human liver tissue indicate that valsartan is a substrate of the hepatic uptake transporter OATP1B1; coadministration with OATP1B1 inhibitors may increase valsartan systemic exposure</p></li><li>piroxicam<p>valsartan and piroxicam both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>piroxicam decreases effects of valsartan by pharmacodynamic antagonism. Modify Therapy/Monitor Closely.  NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.<span><br><br></span>valsartan, piroxicam.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>pitavastatin<p>valsartan increases toxicity of pitavastatin by Other (see comment). Use Caution/Monitor. 
Comment: OATP1B1 inhibitors may increase risk of myopathy.</p></li><li>potassium acid phosphate<p>valsartan and potassium acid phosphate both increase  serum potassium. Use Caution/Monitor.</p></li><li>potassium chloride<p>valsartan and potassium chloride both increase  serum potassium. Use Caution/Monitor.</p></li><li>potassium citrate<p>valsartan and potassium citrate both increase  serum potassium. Use Caution/Monitor.</p></li><li>potassium citrate/citric acid<p>valsartan and potassium citrate/citric acid both increase  serum potassium. Use Caution/Monitor.</p></li><li>pravastatin<p>pravastatin will increase the level or effect of valsartan by  Other (see comment). Use Caution/Monitor. The results from an in vitro study with human liver tissue indicate that valsartan is a substrate of the hepatic uptake transporter OATP1B1; coadministration with OATP1B1 inhibitors may increase valsartan systemic exposure<span><br><br></span>valsartan increases toxicity of pravastatin by Other (see comment). Use Caution/Monitor. 
Comment: OATP1B1 inhibitors may increase risk of myopathy.</p></li><li>propranolol<p>valsartan and propranolol both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>propranolol, valsartan. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of fetal compromise if given during pregnancy.</p></li><li>repaglinide<p>repaglinide will increase the level or effect of valsartan by  Other (see comment). Use Caution/Monitor. The results from an in vitro study with human liver tissue indicate that valsartan is a substrate of the hepatic uptake transporter OATP1B1; coadministration with OATP1B1 inhibitors may increase valsartan systemic exposure</p></li><li>rifampin<p>rifampin will increase the level or effect of valsartan by  Other (see comment). Use Caution/Monitor. The results from an in vitro study with human liver tissue indicate that valsartan is a substrate of the hepatic uptake transporter OATP1B1; coadministration with OATP1B1 inhibitors may increase valsartan systemic exposure</p></li><li>ritonavir<p>ritonavir will increase the level or effect of valsartan by  Other (see comment). Use Caution/Monitor. The results from an in vitro study with human liver tissue indicate that valsartan is a substrate of the hepatic uptake transporter OATP1B1; coadministration with OATP1B1 inhibitors may increase valsartan systemic exposure<span><br><br></span>ritonavir will increase the level or effect of valsartan by  Mechanism: decreasing hepatic clearance. Use Caution/Monitor. The results from an in vitro study with human liver tissue indicate that valsartan is a substrate of the hepatic efflux transporter MRP2; coadministration of inhibitors of the efflux transporter may increase the systemic exposure to valsartan</p></li><li>rosiglitazone<p>rosiglitazone will increase the level or effect of valsartan by  Other (see comment). Use Caution/Monitor. The results from an in vitro study with human liver tissue indicate that valsartan is a substrate of the hepatic uptake transporter OATP1B1; coadministration with OATP1B1 inhibitors may increase valsartan systemic exposure</p></li><li>salicylates (non-asa)<p>valsartan and salicylates (non-asa) both increase  serum potassium. Use Caution/Monitor.</p></li><li>salsalate<p>valsartan and salsalate both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>salsalate decreases effects of valsartan by pharmacodynamic antagonism. Modify Therapy/Monitor Closely.  NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.<span><br><br></span>valsartan, salsalate.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>saquinavir<p>saquinavir will increase the level or effect of valsartan by  Other (see comment). Use Caution/Monitor. The results from an in vitro study with human liver tissue indicate that valsartan is a substrate of the hepatic uptake transporter OATP1B1; coadministration with OATP1B1 inhibitors may increase valsartan systemic exposure</p></li><li>sildenafil<p>sildenafil will increase the level or effect of valsartan by  Other (see comment). Use Caution/Monitor. The results from an in vitro study with human liver tissue indicate that valsartan is a substrate of the hepatic uptake transporter OATP1B1; coadministration with OATP1B1 inhibitors may increase valsartan systemic exposure</p></li><li>simvastatin<p>simvastatin will increase the level or effect of valsartan by  Other (see comment). Use Caution/Monitor. The results from an in vitro study with human liver tissue indicate that valsartan is a substrate of the hepatic uptake transporter OATP1B1; coadministration with OATP1B1 inhibitors may increase valsartan systemic exposure</p></li><li>sofosbuvir/velpatasvir<p>sofosbuvir/velpatasvir increases levels of valsartan by Other (see comment). Use Caution/Monitor. 
Comment: Velpatasvir inhibits OATP1B1, OATP1B3, and OATP2B1 transporters. .</p></li><li>sotalol<p>valsartan and sotalol both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>sotalol, valsartan. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of fetal compromise if given during pregnancy.</p></li><li>spironolactone<p>valsartan and spironolactone both increase  serum potassium. Modify Therapy/Monitor Closely.</p></li><li>sulfasalazine<p>valsartan and sulfasalazine both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>sulfasalazine decreases effects of valsartan by pharmacodynamic antagonism. Modify Therapy/Monitor Closely.  NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.<span><br><br></span>valsartan, sulfasalazine.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>sulindac<p>valsartan and sulindac both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>sulindac decreases effects of valsartan by pharmacodynamic antagonism. Modify Therapy/Monitor Closely.  NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.<span><br><br></span>valsartan, sulindac.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>tadalafil<p>tadalafil increases effects of valsartan by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension.</p></li><li>telithromycin<p>telithromycin will increase the level or effect of valsartan by  Other (see comment). Use Caution/Monitor. The results from an in vitro study with human liver tissue indicate that valsartan is a substrate of the hepatic uptake transporter OATP1B1; coadministration with OATP1B1 inhibitors may increase valsartan systemic exposure</p></li><li>telmisartan<p>telmisartan and valsartan both increase  serum potassium. Use Caution/Monitor.</p></li><li>terbutaline<p>valsartan increases and terbutaline decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>timolol<p>valsartan and timolol both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>timolol, valsartan. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of fetal compromise if given during pregnancy.</p></li><li>tinzaparin<p>tinzaparin increases toxicity of valsartan by Other (see comment). Use Caution/Monitor. 
Comment: Low molecular weight heparins may suppress adrenal aldosterone secretion, which can potentially cause hyperkalemia.</p></li><li>tizanidine<p>tizanidine increases effects of valsartan by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension.</p></li><li>tolfenamic acid<p>valsartan and tolfenamic acid both increase  serum potassium. Use Caution/Monitor.</p></li><li>tolmetin<p>valsartan and tolmetin both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>tolmetin decreases effects of valsartan by pharmacodynamic antagonism. Modify Therapy/Monitor Closely.  NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.<span><br><br></span>valsartan, tolmetin.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>tolvaptan<p>valsartan and tolvaptan both increase  serum potassium. Use Caution/Monitor.</p></li><li>torsemide<p>valsartan increases and torsemide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>treprostinil<p>treprostinil increases effects of valsartan by pharmacodynamic synergism. Use Caution/Monitor.</p></li><li>triamterene<p>valsartan and triamterene both increase  serum potassium. Modify Therapy/Monitor Closely.</p></li><li>trimethoprim<p>valsartan and trimethoprim both increase  serum potassium. Use Caution/Monitor. Trimethoprim decreases urinary potassium excretion. May cause hyperkalemia, particularly with high doses, renal insufficiency, or when combined with other drugs that cause hyperkalemia.</p></li><li>xipamide<p>xipamide increases effects of valsartan by pharmacodynamic synergism. Use Caution/Monitor.</p></li>